Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study
International Journal of Environmental Research and Public Health · 2023
DOI: 10.3390/ijerph20043703 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift International Journal of Environmental Research and Public Health, 2023. Verfasst von Rebecca Amati und 19 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Public Health, Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss School of Public Health, Ceresio Foundation.
Abstract (Originalsprache)
Objectives
The COVID-19 pandemic continues, and evidence on infection- and vaccine-induced immunity is key. We assessed COVID-19 immunity and the neutralizing antibody response to virus variants across age groups in the Swiss population. Study Design: We conducted a cohort study in representative community-dwelling residents aged five years or older in southern Switzerland (total population 353,343), and we collected blood samples in July 2020 (in adults only, N = 646), November–December 2020 (N = 1457), and June–July 2021 (N = 885).
Methods
We used a previously validated Luminex assay to measure antibodies targeting the spike (S) and the nucleocapsid (N) proteins of the virus and a high-throughput cell-free neutralization assay optimized for multiple spike protein variants. We calculated seroprevalence with a Bayesian logistic regression model accounting for the population’s sociodemographic structure and the test performance, and we compared the neutralizing activity between vaccinated and convalescent participants across virus variants.
Results
The overall seroprevalence was 7.8% (95% CI: 5.4–10.4) by July 2020 and 20.2% (16.4–24.4) by December 2020. By July 2021, the overall seroprevalence increased substantially to 72.5% (69.1–76.4), with the highest estimates of 95.6% (92.8–97.8) among older adults, who developed up to 10.3 more antibodies via vaccination than after infection compared to 3.7 times more in adults. The neutralizing activity was significantly higher for vaccine-induced than infection-induced antibodies for all virus variants (all p values < 0.037).
Conclusions
Vaccination chiefly contributed to the reduction in immunonaive individuals, particularly those in older age groups. Our findings on the greater neutralizing activity of vaccine-induced antibodies than infection-induced antibodies are greatly informative for future vaccination campaigns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Public Health, Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.
- Fondazione Agnelli, 10125 Turin, Italy.
- Faculty of Informatics, Università della Svizzera italiana, 6900 Lugano, Switzerland.
- Department of Business Economics, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland, 6928 Manno, Switzerland.
- Department of Health Sciences, University of Lucerne, 6002 Lucerne, Switzerland.
- Institute of Microbiology, University of Applied Sciences and Arts of Southern Switzerland, 6501 Bellinzona, Switzerland.
ORCID-Profile: Rebecca Amati, Anne-Linda Camerini, Marta Fadda, Maddalena Fiordelli, Anna Maria Annoni, Serena Sabatini, Marco Kaufmann, Anja Frei, Luca Crivelli
Förderung
- Swiss School of Public Health
- Ceresio Foundation
Zitieren
APA
Amati, R., Piumatti, G., Franscella, G., Buttaroni, P., Camerini, A. L., Corna, L., Levati, S., Fadda, M., Fiordelli, M., Annoni, A. M., Bezani, K., Amendola, A., Fragoso Corti, C., Sabatini, S., Kaufmann, M., Frei, A., Puhan, M. A., Crivelli, L., Albanese, E., & On Behalf Of The Corona Immunitas Ticino Study Group (2023). Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph20043703
Vancouver
Amati R, Piumatti G, Franscella G, Buttaroni P, Camerini AL, Corna L, et al. Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study. International Journal of Environmental Research and Public Health. 2023. doi:10.3390/ijerph20043703
BibTeX
@article{Amati2023,
author = {Amati, Rebecca and Piumatti, Giovanni and Franscella, Giovanni and Buttaroni, Peter and Camerini, Anne-Linda and Corna, Laurie and Levati, Sara and Fadda, Marta and Fiordelli, Maddalena and Annoni, Anna Maria and Bezani, Kleona and Amendola, Antonio and Fragoso Corti, Cristina and Sabatini, Serena and Kaufmann, Marco and Frei, Anja and Puhan, Milo Alan and Crivelli, Luca and Albanese, Emiliano and On Behalf Of The Corona Immunitas Ticino Study Group},
title = {Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study},
journal = {International Journal of Environmental Research and Public Health},
year = {2023},
doi = {10.3390/ijerph20043703}
}
EUVIMED